ArticleAquaculture nutrition2026
Ulvan Microparticles for Encapsulation of Eucalyptus Essential Oil: Characterization, Release Behavior, and Stability in Aquafeeds.
Article in Aquaculture nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ulvan Microparticles for Encapsulation of Eucalyptus Essential Oil: Characterization, Release Behavior, and Stability in Aquafeeds.Aquaculture nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulvan-lecithin microstructures were developed as a delivery platform for eucalyptus essential oil (EEO) in functional aquafeeds to improve phytobiotic retention, modulate gastrointestinal release, and enhance pellet stability during storage. Preliminary formulation screening compared ulvan-only and ulvan-lecithin systems containing different lecithin levels. Among the tested formulations, ulvan-1%-lecithin-EEO (U-L1-EEO) showed the most favorable overall profile, with the highest encapsulation efficiency (EE%, 76.4% ± 1.2%), the lowest surface-associated EEO fraction (23.6% ± 1.2%), a median particle size of 145.2 ± 4.8 μm, a narrow size distribution (span = 1.33 ± 0.04), and a negative ζ-potential (-31.6 ± 1.8 mV). Fourier-transform infrared (FTIR) spectroscopy and differential scanning calorimetry (DSC) analyses supported the formation of a physically stabilized ulvan-lecithin matrix and the incorporation of EEO through mainly noncovalent interactions. In PBS (pH 7.4), U-L1-EEO exhibited sustained release, reaching ~90% after 24 h, with Higuchi and Korsmeyer-Peppas modeling indicating diffusion-governed and anomalous transport behavior during the initial release phase. Under simulated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.